Floatz logo

gi-6301

mCRC

ImmunityBio, Inc.vaccinePhase 1/2Dormant
D
31/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
16/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the mCRC cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Shanghai Henlius Biotech
Phase 2B
Calcium folinate pentahydrate
Shanghai Henlius Biotech
Phase 2B
Eloxatin
Shanghai Henlius Biotech
Phase 2B
Pelareorep
Oncolytics Biotech
Phase 2CCC
Irinotecan
Oncolytics Biotech
Phase 2CCC

View all 20 →

Same molecule, other indications

gi-6301 is also rated in:

triple-negative breast carcinomaDormant
C
Indicative ·
38 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
38 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →